Preclinical and clinical evidence suggests that the combination of BRAFi/MEKi and checkpoint inhibitors (anti-PD-1 and anti-PD-L1) could be a good strategy to overcome resistance to BRAF inhibition, providing durable responses in a high rate of metastatic melanoma patients thanks to the activity of BRAFi to enhance immune activation. This evidence concerns the gene BRAF and melanoma.